Literature DB >> 34693931

Associations Between Central Obesity and Lifelong Antiviral Therapy in Adults Living With HIV Acquired From Early Childhood.

Seynt Jiro Sahagun1, Teja Yeramosu1, Julia B Purdy2, James C Reynolds3, Colleen M Hadigan1.   

Abstract

BACKGROUND: Little is known regarding the long-term effects of antiretroviral (ARV) exposure on body composition for people living with HIV (PLWH) since early childhood. This study explores changes in body fat distribution in relation to ARV exposure.
METHODS: We conducted a prospective study of adults with perinatal HIV (n = 70) using dual-energy X-ray absorptiometry and standard anthropometrics. Trunk to limb fat ratio and waist to hip ratio were compared cross-sectionally to 47 matched controls. Furthermore, changes in body composition and ARV exposure were evaluated longitudinally in a subset of 40 PLWH with a median follow-up of 7 years.
RESULTS: Cross-sectional comparisons of PLWH with controls revealed significantly higher waist to hip ratio, trunk to limb fat ratio, HOMA-IR, and triglycerides, whereas BMI did not differ. Among PLWH with longitudinal follow-up, the prevalence of overweight increased from 27.5% to 52.5% and obesity from 12.5% to 25%; waist to hip and trunk to limb fat ratios also increased (P < 0.0001). Changes in waist to hip ratio were positively correlated with longer exposure during follow-up to darunavir (r = 0.36; P = 0.02), whereas increases in trunk to limb fat ratio were positively correlated with longer exposure to stavudine (r = 0.39; P = 0.01) and didanosine (r = 0.39; P = 0.01) but inversely associated with emtricitabine (r = -0.33; P = 0.04). Increases in waist to hip ratio were correlated with increases in triglyceride levels (r = 0.35; P = 0.03).
CONCLUSION: This study presents strong evidence for persistent and worsening central adiposity in young adults with lifelong HIV and extensive ARV exposure. As this cohort ages, continued evaluation of the body composition and metabolic impact of lifelong ARV therapy is warranted to optimize long-term health.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34693931      PMCID: PMC8752474          DOI: 10.1097/QAI.0000000000002841

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.771


  33 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.

Authors:  José R Santos; María Saumoy; Adrian Curran; Isabel Bravo; Josep M Llibre; Jordi Navarro; Carla Estany; Daniel Podzamczer; Esteban Ribera; Eugènia Negredo; Bonaventura Clotet; Roger Paredes
Journal:  Clin Infect Dis       Date:  2015-04-13       Impact factor: 9.079

3.  Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.

Authors:  Judith A Aberg; Pablo Tebas; Edgar Turner Overton; Samir K Gupta; Paul E Sax; Alan Landay; Ron Falcon; Robert Ryan; Guy De La Rosa
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-02       Impact factor: 2.205

Review 4.  Impact of nevirapine on lipid metabolism.

Authors:  Bonaventura Clotet; Marc van der Valk; Eugenia Negredo; Peter Reiss
Journal:  J Acquir Immune Defic Syndr       Date:  2003-09       Impact factor: 3.731

5.  Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.

Authors:  Eugenia Negredo; Josep Ribalta; Roger Paredes; Raimón Ferré; Guillem Sirera; Lidia Ruiz; Juliana Salazar; Peter Reiss; Lluís Masana; Bonaventura Clotet
Journal:  AIDS       Date:  2002-07-05       Impact factor: 4.177

6.  Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Authors:  Linda Aurpibul; Thanyawee Puthanakit; Benjamin Lee; Ampica Mangklabruks; Thira Sirisanthana; Virat Sirisanthana
Journal:  Antivir Ther       Date:  2007

Review 7.  Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.

Authors:  Leonardo Calza; Roberto Manfredi; Francesco Chiodo
Journal:  J Antimicrob Chemother       Date:  2003-11-25       Impact factor: 5.790

8.  Long-Term Changes of Subcutaneous Fat Mass in HIV-Infected Children on Antiretroviral Therapy: A Retrospective Analysis of Longitudinal Data from Two Pediatric HIV-Cohorts.

Authors:  Sophie Cohen; Steve Innes; Sibyl P M Geelen; Jonathan C K Wells; Colette Smit; Tom F W Wolfs; Berthe L F van Eck-Smit; Taco W Kuijpers; Peter Reiss; Henriette J Scherpbier; Dasja Pajkrt; Madeleine J Bunders
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

9.  Metabolic risk factors in young adults infected with HIV since childhood compared with the general population.

Authors:  Elise Arrive; Jean-Paul Viard; Benoît Salanave; Catherine Dollfus; Sophie Matheron; Véronique Reliquet; Elisa Arezes; Laura Nailler; Corinne Vigouroux; Josiane Warszawski
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

10.  Metabolic syndrome, biochemical markers, and body composition in youth living with perinatal HIV infection on antiretroviral treatment.

Authors:  Linda Aurpibul; Sirianong Namwongprom; Tavitiya Sudjaritruk; Sakaewan Ounjaijean
Journal:  PLoS One       Date:  2020-03-30       Impact factor: 3.240

View more
  2 in total

Review 1.  Ectopic Fat and Cardiac Health in People with HIV: Serious as a Heart Attack.

Authors:  Ana N Hyatt; Jordan E Lake
Journal:  Curr HIV/AIDS Rep       Date:  2022-08-13       Impact factor: 5.495

Review 2.  Roles of Interleukin-6-mediated immunometabolic reprogramming in COVID-19 and other viral infection-associated diseases.

Authors:  Ying-Shuang Li; Hua-Cheng Ren; Jian-Hua Cao
Journal:  Int Immunopharmacol       Date:  2022-06-28       Impact factor: 5.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.